Literature DB >> 26351488

Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast.

Sepideh Siadati1, Majid Sharbatdaran1, Novin Nikbakhsh2, Naser Ghaemian3.   

Abstract

BACKGROUND AND OBJECTIVES: Breast cancer is the most common malignancy among women in the world. The aim of this study was to assess estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu of infiltrating ductal carcinoma (IDC) with tumor size, histologic grade, lymph node metastasis and age.
METHODS: This study was carried out on 300 tissue blocks of patients with IDC who underwent mastectomy from 2007 to 2011 in Shahid Beheshti Hospital, affiliated to Babol University of Medical Sciences, Babol, Iran. Data including age, tumor size, and histologic grade and lymph node status retrieved from pathology department. RESULT: The mean age of the patients was 40.2±2.3 (ranged 19-82 years). ER and PR were positively correlated with each other ( P = 0.001) and they inversely correlated with HER-2/neu ( P =0.001). We observed correlation between ER and PR expression and low histologic grade ( P = 0.001) and HER-2/neu expression and high histologic grade ( P = 0.003). There was correlation between HER-2/neu expression and lymph node involvement ( P =0.03). None of these makers showed correlation with age and tumor size ( P > 0.05).
CONCLUSION: Our findings indicate the importance of ER, PR and HER-2/neu expression as prognostic factors for therapeutic decision.

Entities:  

Keywords:  Breast; Estrogen Receptors; Invasive Ductal Carcinoma; Progesterone Receptor; c-erbB-2 Proto-Oncogene

Year:  2015        PMID: 26351488      PMCID: PMC4539777     

Source DB:  PubMed          Journal:  Iran J Pathol        ISSN: 1735-5303


  19 in total

1.  Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.

Authors:  Joshua Nyagol; Aggrey Nyong'o; Bessie Byakika; Lucy Muchiri; Mario Cocco; M M de Santi; Donatella Spina; Cristiana Bellan; Stefano Lazzi; Ioannis Kostopoulos; Pietro Luzi; Lorenzo Leoncini
Journal:  Anal Quant Cytol Histol       Date:  2006-04       Impact factor: 0.302

2.  Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Authors:  Raquel Prati; Sophia K Apple; Jianbo He; Jeffrey A Gornbein; Helena R Chang
Journal:  Breast J       Date:  2005 Nov-Dec       Impact factor: 2.431

3.  Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

Authors:  M Ferrero-Poüs; K Hacène; C Bouchet; V Le Doussal; M Tubiana-Hulin; F Spyratos
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

4.  Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.

Authors:  Fusun Tokatli; Tokatli Fusun; Semsi Altaner; Altaner Semsi; Cem Uzal; Uzal Cem; Mevlut Ture; Ture Mevlut; Zafer Kocak; Kocak Zafer; Kazim Uygun; Uygun Kazim; Selcuk Bilgi; Bilgi Selcuk
Journal:  Exp Oncol       Date:  2005-06

5.  Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes.

Authors:  I Mittra; A A Redkar; R A Badwe
Journal:  J Surg Oncol       Date:  1995-10       Impact factor: 3.454

6.  C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

7.  Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.

Authors:  Moses Ambroise; Mitra Ghosh; V S Mallikarjuna; Ann Kurian
Journal:  Asian Pac J Cancer Prev       Date:  2011

8.  Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.

Authors:  J M Bhatavdekar; D D Patel; N G Shah; H H Vora; T P Suthar; P R Chikhlikar; N Ghosh; T I Trivedi
Journal:  Ann Surg Oncol       Date:  2000-05       Impact factor: 5.344

9.  Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.

Authors:  Tatjana Ivkovic-Kapicl; Slavica Knezevic-Usaj; Dragana Djilas-Ivanovic; Milana Panjkovic
Journal:  In Vivo       Date:  2007 Jul-Aug       Impact factor: 2.155

10.  The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients.

Authors:  Toshinao Onoda; Hideko Yamauchi; Hiroshi Yagata; Koichiro Tsugawa; Naoki Hayashi; Atsushi Yoshida; Koyu Suzuki; Osamu Sakurai; Seigo Nakamura
Journal:  Breast Cancer       Date:  2013-10-01       Impact factor: 4.239

View more
  4 in total

1.  Clinical features and first degree relative breast cancer, their correlation with histological tumor grade: a 5-year retrospective case study of breast cancer in Mizoram, India.

Authors:  Doris Zodinpuii; Jeremy Lalrinsanga Pautu; Bawitlung Zothankima; Lalawmpuii Pachuau; Nachimuthu Senthil Kumar
Journal:  Environ Sci Pollut Res Int       Date:  2019-11-25       Impact factor: 4.223

2.  Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study.

Authors:  Ahmed M Abd El-Aziz; Eman A Ibrahim; Ashraf Abd-Elmoghny; Mohammed El-Bassiouny; Zina M Laban; Somaia A Saad El-Din; Youhanna Shohdy
Journal:  Cancer Growth Metastasis       Date:  2017-02-16

3.  The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases inzzm321990Indonesian Woman

Authors:  Yunita Setyawati; Yeni Rahmawati; Irianiwati Widodo; Ahmad Ghozali; Dewajani Purnomosari
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

4.  Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use.

Authors:  Prem Chand; Anubha Garg; Vandana Singla; Nisha Rani
Journal:  Niger J Surg       Date:  2018 Jul-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.